Tumor-Targeted Drug Delivery

In the rapidly evolving field of nano-bio research, innovation is the name of the game. Our team is at the forefront of this exciting intersection of nanotechnology and biology, pushing boundaries and exploring new frontiers. Each member brings unique expertise and passion, contributing to groundbreaking discoveries that have the potential to transform healthcare and environmental sustainability.

Our research focuses on the design of advanced tumor-targeted drug delivery systems using silica-based nanomaterials and multifunctional hybrid nanoparticles to achieve precise, stimuli-responsive cancer therapy with minimal off-target toxicity.

Core Concept

Conventional chemotherapy often fails due to poor selectivity and systemic side effects. To overcome these limitations, I develop engineered nanocarriers that selectively recognize cancer cells, enter them efficiently, and release therapeutic payloads only in the tumor microenvironment.

Nanomaterial Platforms

• Mesoporous silica nanoparticles (MSNs) as primary carriers due to their:

  • High surface area and tunable pore size

  • Excellent drug-loading capacity

  • Easy surface functionalization

• Hybrid nanocomposites incorporating polymers, metal/metal-oxide nanoparticles, and carbon-based materials to enable multi-stimuli responsiveness.

Targeting Strategy: Receptor-Mediated Endocytosis

Nanocarriers are functionalized with tumor-specific ligands (e.g., peptides, antibodies, folate, sugars) that bind overexpressed receptors on cancer cells.This enables:

• Selective cellular uptake

• Enhanced intracellular drug accumulation

• Reduced damage to healthy tissues

Smart, Tumor-Responsive Drug Release

The systems are engineered to respond to intracellular and tumor-specific triggers, ensuring on-demand drug release:

• pH-Responsive ReleaseExploits the acidic tumor microenvironment and endo-lysosomal compartments to trigger drug release.

• GSH-Triggered ReleaseUtilizes elevated intracellular glutathione levels in cancer cells to cleave redox-sensitive linkers.

• ROS/RNS-Responsive SystemsTakes advantage of high reactive oxygen and nitrogen species in tumors to induce carrier degradation or gate opening.

• Thermal (Heat)-Triggered ReleaseIntegrates photothermal or magnetic components for externally controlled drug release under localized hyperthermia.

Therapeutic Impact

This multi-stimuli approach allows:

• High therapeutic precision

• Controlled and sequential drug release

• Improved anticancer efficacy

• Reduced systemic toxicity and drug resistance

Broader Vision

The ultimate goal of this research is to develop clinically translatable nanomedicine platforms that combine targeting, sensing, and therapy into a single system—paving the way for personalized and next-generation cancer treatments.